Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (120)	9/13/2000 9:33:14 PM
From: Miljenko Zuanic	Respond to of 447

AstraZeneca Lung Cancer Product Shows Early Promise -------------------------------------------------------------------------------- LONDON, Sep 13 (Reuters Health) - AstraZeneca's anticancer agent Iressa (ZD1839) can stop non-small cell lung cancer from progressing and even cause tumor shrinkage, according to phase l data presented on Tuesday at the World Congress on Lung Cancer, held in Tokyo. "We were surprised and encouraged to see clinical responses at this early stage of development as these early clinical evaluations of ZD1839 were essentially designed just to assess the safety of the compound in patients and to find the right dose to take forward into larger clinical trials," Dr. Mark Kris, chief of the thoracic oncology service at the Memorial Sloan-Kettering Cancer Center in New York, said. AstraZeneca said in a news release that ZD1839 is now being studied by clinicians internationally in large randomized multinational trials. The drug is designed to block the epidermal growth factor receptor, which is implicated in the growth of a number of common solid tumors.